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primary brain neoplasms, chiefly occurring between 30 and
50 years of age [1]. With recent advances in molecular genetics,
it has been found that molecular subtype is a better predictor of
prognosis than classical histology [2,3]. The 2016 WHO classifica-
tion of glioma is based on a genotype-driven classification of dif-
fuse gliomas [4]. The grade 2 gliomas have been subdivided
along the presence or absence of a mutation in the isocytrate dehy-
drogenase 1 or 2 (IDH). The group of tumors with a mutation pre-
sent in the IDH gene (IDHmG) have a relatively favorable
prognosis, while group of IDH wildtype (IDHwt) tumors have a
prognosis more akin to glioblastoma [5,6].
The objective of radiotherapy in low grade glioma is an
extended period of local control. The place of postoperative radio-
therapy and chemotherapy in grade 2 glioma was established by
the results of several multicenter trials [7–9]. After a disease-free
interval, a subset of low grade glioma are known to undergo malig-
nant transformation, almost invariably inside or in close proximity
to the radiation field.
Improvements in imaging, neurosurgical technique, and the
introduction of adjuvant chemotherapy over the past 20 years have
increased the prognosis of LGG patients considerably. As such,
there has been a shift in focus from achieving disease control
towards reducing the late adverse effects of radiotherapy. The
use of radiotherapy, especially the large fields applied in the past,
has been implicated in the onset of late neurocognitive decline
[10]. Recent trials have reduced the GTV-CTV expansion to10 mm (NRG BN005, NCT03180502) or 5 mm (EORTC 1635,
NCT03763422). The current working document of the Dutch Plat-
form for Radiotherapy in Neuro-Oncology advises a margin of
5 mm to be used in clinical care. However, effect of these smaller
fields on pattern of failure is not yet known. We sought to assess
the safety of a CTV margin reduction to 5 mm using a retrospective
analysis of historical treatments of IDHmt low grade glioma
patients using the 2011 RANO criteria for progressive disease [11].
Methods and materials
Patient population
We reviewed the charts of all patients treated with radiother-
apy for histologically confirmed low grade glioma between 1-1-
2007 and 31-12-2017 in Erasmus MC. Of the patients exhibiting
disease progression, the original planning CT, structure set, and
dose object were retrieved. In patients in which the IDH status
was not known, IDH was sequenced from archived material.
Finally, a number of cases in which IDH status was known from a
separate project [12] were found to have disease progression on
follow-up. Data from these cases was requested from their treating
centers. The study was conducted according to the principles of the
Declaration of Helsinki (59th WMA General Assembly, Seoul, Octo-
ber 2008) and in accordance with the local medical research regu-
lations. The study protocol was presented to the local Medical
Ethics Committee (MEC-2019-255) and considered not subject to
the Medical Research Involving Human Subjects Act.Event definition
Resection status was defined as either biopsy only, complete
resection (if no residual tumor mass was reported on postoperative
Table 1
Patient characteristics.
Age (years) 42.1 (95% CI 39.1 –
45.1)
Sex Male 26 66.6%
Female 13 33.3%
Hemisphere Right 16 41.0%
Left 19 48.7%
Both 4 10,3%





Overlapping lesion 3 7.7%




Gross total resection 4 10.3%
Unknown 1 2.6%
1p/19q codeletion Present 17 43.6%
Absent 17 43.6%
Undetermined 5 12.8%
Technique 3DCT 25 64.1%
IMRT 14 35.9%
CTV margin 10 mm 10 25.6%
Pattern of failure in IDH mutated low grade glioma after radiotherapyimaging) or partial (if residual tumor mass was present). Follow up
MRI’s typically included of at least T1 weighed pre- and post-
contrast, 2d T2 weighed and FLAIR images. All available MRI’s were
reviewed. Type of recurrence was defined according to Response
Assessment in Neuro Oncology (RANO) criteria as either enhancing
(development of a new contrast enhancing lesion) or non-
enhancing (an increase of 25% in perpendicular diameter of T2
abnormalities without enhancement). The date of progressive dis-
ease (PDRANO) was the date of the first MRI that fulfilled the RANO
criteria for recurrence. Time to progression (TTP) was defined as
the interval between the last RT fraction and the date of progres-
sive disease according to the RANO criteria. In all centers, it was
customary to confirm the diagnosis of recurrence in a multidisci-
plinary neuro-oncological tumor board before a next intervention
was started. The date on which the diagnosis of recurrence was
confirmed by the tumor board was defined as ‘‘tumor-board pro-
gressive disease” (PDtb). In order to avoid transient contrast-
enhancing lesions being interpreted as disease recurrence we con-
firm the presence of these lesions over sequential MRIs between
PDRANO until PDtb. Adjuvant chemotherapy was defined as
chemotherapy started within 3 months after completion of radio-
therapy in absence of disease progression.15 mm 29 74.4%






PCV 2 5.1%Volumetric analysis
The MRI at time of PDRANO was rigidly matched to the original
planning CT using MIM (MIM software, version 6.3.9, Cleveland,
Ohio). In patients with an enhancing recurrence, the recurrence
volume (rTV) was defined as the area of pathological enhancement
on T1 series. In patients without an enhancing recurrence, the
recurrence volume was defined as the areas of T2 hypo-
attenuation that exhibited progression over the preceding
12 months. The volumes were delineated by AMR and JJ (radiation
oncologists), and delineations were approved by MvdB
(neurologist).
A hypothetical CTV of 5 mm (CTV5mm) was generated by cre-
ating a 5 mm expansion of the original GTV, and limiting this to
within the original CTV. The overlap between the rTV, the original
CTV, the CTV5mm and the original 95% isodose volume was calcu-
lated. Recurrence was classified as either central (>95%), inside
(>80–95%), edge (>20–80%), or outside (20%) of the original
CTV. Dose volume histograms (DVH) were generated for all recur-
rences. The distribution of recurrences with regards to the original
CTV and the CTV5mm was compared using a two-way ANOVA.
Overall survival and progression free survival were assessed using
a Kaplan-Meier analysis. Statistical analysis was done in R (www.r-
project.org) and SPSS (IBM Corp., IBM SPSS Statistics for Windows,
Version 25.0.0.1, Armonk, New York).Results
Between 1-5-2007 and 31-12-2017, 113 patients underwent
radiotherapy for low grade glioma. A recurrence was diagnosed
in 56 patients. Radiotherapy planning and delineation could be
retrieved in 49 of these patients. In 35 of these patients a positive
IDH mutation status was found. Four additional fully documented
cases with known IDH status and disease recurrence were added
from two centers. The final dataset comprised 39 IDHmG patients
with known recurrence. Patient characteristics are summarized in
Table 1.
Mean age at diagnosis was 42.1 years (95% CI 39.6–45.7). Resec-
tion status was gross total resection in 4 patients (10%), partial
resection in 23 (59%), biopsy in 11 patients (28%), and unknown
in one patient (3%). A 1p/19q deletion was present in 17 patients
(44%), absent in 17 patients (44%) and undetermined in 5 patients44(13%). Median interval between surgery and start of radiotherapy
was 0.3 years (range 0.2–12.0). All patients were treated to a dose
of 50.4 Gy in 28 fractions (ICRU 50). Patients were treated with
either 3DCT (64%) or IMRT (36%). GTV-CTV margin was 15 mm in
29 patients (74%), and 10 mm in 10 patients (26%). The mean
CTV volume was 294 cc (95% CI 252–336). PTV margin was
5 mm in all patients. Four patients (10%) were treated with adju-
vant chemotherapy.
By the time of analysis the median duration of follow-up from
end of radiotherapy was 5.0 years (range 1.4–11.4). Median overall
survival was 5.6 years (range 1.3–11.4), with 24 patients having
died of disease. Median TTP was 2.8 years (range 0.6–9.3). In 21
patients, the date of PDRANO was within 14 days of the date of PDtb.
However, in 18 patients the date of PDRANO predated the date PDtb
by a median of 0.5 years (range 0.1–3.0). Time intervals and sur-
vival are summarized in Fig. 1.
At the time of PDRANO 34 patients developed an enhancing
recurrence (87%) and five patients (13%) developed a non-
enhancing recurrence. The mean volume of the rTV of enhancing
recurrences was 5.2 cc (range 0.1–37.7). The mean volume of the
rTV of non-enhancing recurrences was 32.8 cc (range 2.4–140.3).
With regards to the original CTV, recurrences were classified as
central in 32 (82%), inside in 3 (8%), edge in 1 (2%) and outside in
3 patients (8%). Almost all recurrences (92%) were covered by the
95% isodose line, three (8%) were out-field. Based on the hypothet-
ical CTV5mm, recurrences would have been central in 26 (66%),
inside in 4 (10%), edge in 5 (13%), and outside in 4 (10%) patients
(Fig. 2). The difference in distribution of recurrence clas was signif-
icant (p = 0.005). See Fig. 3 for two examples of recurrences. Owing
to the low number of non-enhancing recurrences, we were unable
to test whether the distribution of recurrence class differs between
enhancing and non-enhancing recurrences. However, the probabil-
ity of a central recurrence was higher in enhancing recurrences
(88%) than in non-enhancing recurrences (40%, p = 0.03, see Sup-
plementary data 1). The mean dose to 98% of the rTV (D98%) was
50.4 Gy in the recurrences classified as central with respect to
Fig. 1. Waterfall plot of time intervals for all patients from diagnosis until
end of follow-up. PDRANO = progressive disease as defined by the RANO criteria.
PDtb = progressive disease confirmed by the multidisciplinary tumor board.
J.P.M. Jaspers, A. Méndez Romero, R. Wiggenraad et al. Radiotherapy and Oncology 156 (2021) 43–48the CTV (range 48.4–54.4), 48.8 Gy in the inside category
(range 48.6–49.2), 44.1 Gy in the one edge recurrence, and
14.7 Gy (range 1.5–34.4) in the outside category (see Supplemen-
tary data 2 and 3).Discussion
The size of the treatment field has been a point of contention
since the introduction of radiotherapy for glioma. Historically, pro-
ponents of partial brain techniques argued a smaller treatment
field would lead to less adverse effects and potential for dose esca-
lation [13–15], while proponents of whole brain radiotherapy
emphasized the risk of out-field failure in light of uncertainties
in target localization [16,17]. Following the availability of CT and
MRI imaging, the landmark trials in low grade glioma of the
1990s and 2000s all adopted target volumes based on some form
of a margin around a lesion visible on imaging of 15 to 20 mm
(Table 2). As no prospective data on smaller treatment marginsFig. 2. Classification of recurrences based on original CTV, the hypothetical 5 mm CTV
regards to the CTV and the CTV5mm is significant (p = 0.005).
45exists, a CTV margin of 10–15 mm is still standard of care in many
centers.
To our knowledge, this study is the first to use a volumetric
approach to classify the pattern of recurrence in IDH mutated,
low grade glioma as defined by the new 2016 WHO classification.
Although varying in methodology, for example, a centroid
approach [18] or visual methods [19], all known studies investigat-
ing pattern of recurrence find the vast majority of failures to occur
within high-dose area of the original treatment field (see Table 3).
In this study, we find a similar pattern of failure in patients treated
between 2007 and 2017 with the dose of 50.4 Gy in 28 fractions
regarded as standard, using a GTV-CTV expansion, a PTV margin,
and photon therapy planning techniques (3DCT, IMRT) that repre-
sented standard of care. The results from the proton therapy cohort
presented by Kamran [19], which dates from 2005 to 2015, suggest
the pattern of failure in proton beam therapy is comparable.
The cases in our cohort were selected for disease progression,
resulting in a median TTP of only 2.8 years after radiotherapy at
a median duration of follow-up of 5.0 years. Contrasting this, the
median TTP in the entire radiotherapy – only group of EORTC
22033–26033 [20] was 3.8 years at a median duration of follow
– up of 4.0 years, reflecting the case selection in this study. It is
notable that all but 4 patients treated in this study date from
before the introduction of adjuvant chemotherapy. Both PCV and
temozolomide chemotherapy are known to inhibit tumor growth
[21,22], and the use of chemotherapy is associated with a benefit
in PFS in IDHmG [7,9]. As the number of patients that received
adjuvant chemotherapy in this study is low, the influence of adju-
vant chemotherapy on the pattern of failure is not known.
The definition of disease progression may influence the pattern
of failure. As the recurrence volume will increase over time, mostly
in a centripetal manner, definition of recurrence at a later time
point will lead to an increasing number of failures in the ‘‘inside”
or ‘‘edge” categories. As an additional observation, we found that
when retrospectively assessing all imaging, PDRANO was found to
predate PDtb almost half of all patients. A similar finding appears
in Izquierdo et al [22], reporting an interval between retrospec-
tively assessed RANO – progressive disease and the next interven-
tion of 11 months. New contrast - enhancing lesions after
radiotherapy are not uncommon and some represent benign
post-treatment changes [23,24]. It is likely that new contrast –
enhancing lesion are observed for a time period in follow up,
before they are considered indicative of disease recurrence. In this
study, the contrast – enhancing lesions that were delineated at
PDRANO were identified with the benefit of hindsight. As such, all
lesions delineated developed into the actual recurrence confirmed
by the tumor board at PDtb.
There are several factors other than the GTV-CTV and tumor
size that determine the size of the treatment field. The size of(CTV5mm), and the 95% isodose. The difference in distribution of recurrences with
Table 2
Overview of specified treatment margins in selected trials, and published pattern of failure for low grade glioma. Note that ICRU29 definition defined a target volume, and ICRU50
report and on define a CTV and a PTV. See [36] for an illustrated overview.
Procedure Target ICRU definition
Completed trials
EORTC 22,844 [31] CT enhancing lesion + 20 mm
CT edema + 10 mm
Target volume ICRU29
EORTC 22,845 [37] MRI T2 abnormalities + 20 mm Target volume ICRU29
RTOG 9802 [9] MRI T2 abnormalities + 20 mm Field edge ICRU29
Intergroup [32] Lesion on CT or MRI + 20 mm Target volume ICRU29
EORTC 22,033–26,033 [20] MRI T1 enhancement and T2 abnormalities + 15 mm CTV ICRU50
Ongoing trials
NRG BN005 NCT03180502 10 mm CTV ICRU50
EORTC 1635 NCT03763422 (QA guideline) 5 mm CTV ICRU50
Table 3
Overview of published studies in low grade glioma with pattern of failure data.
Margin Number of recurrences In field Field edge Out of field
Pu, 1994 [38] 10–30 mm to target volume 11 100% 0% 0%
Rudoler, 1998 [39]* 20 mm to target volume 16 100% 0% 0%
van den Bent, 2005 [37] 20 mm to target volume 94 90% 5% 4%
Shaw, 2002 [32] 20 mm to target volume 65 92% 3% 5%
Kamran, 2019 [19] 7–15 mm to CTV 41 76% 12% 12%
This study 10–15 mm to CTV 39 92% 0% 8%
* The study population included 8 cases treated with whole brain radiotherapy.
Fig. 3. Two examples of recurrences. The dose distribution and the structure set are superimposed on the MRI at the time of recurrence. The GTV is in yellow, the original CTV
is dark blue, the PTV is red. The CTV5mm is in light blue. The rTV is in pink. To the left is a T1 recurrence classified as ‘‘central” with regards to the original CTV, ‘‘inside” with
regards to the CTV5mm, and ‘‘in field” with regards to the 95% isodose. To the right is a parahippocampal (and infratentorial) T2 recurrence classified as out-field.
Pattern of failure in IDH mutated low grade glioma after radiotherapythe GTV is determined in part by the choice of neurosurgical resec-
tion, as the resection cavity will be included in addition to residual
tumor volume. Larger extent resections have been shown to influ-
ence progression-free survival in some series [25,26]. The use of
additional imaging modalities, such as PET, may also increase the
size of the GTV [27]. Even with the use of modern imaging, the
inter – observer variability in GTV delineation is known to be sub-
stantial in diffuse glioma [28]. Uncertainty in target identification
is normally incorporated in the PTV margin, along with other ran-
dom and systemic errors in planning and dose delivery, and as such
may influence the size of the treatment field [29,30].46In interpreting pattern of failure, in-field failure occurs when
insufficient dose was delivered to kill all tumor cells inside the
CTV. Contrasting this, edge failure might be interpreted as a result
of a geographic miss, occurring when the chosen treatment field
failed to encompass the future site of relapse. In low-grade glioma
it is known that dose escalation will result in equal survival at best,
with a potentially negative impact on quality of life [31,32]. Since
an increase in dose using current treatment fields is not opportune,
and in light of the improving prognosis of IDHmG patients, it
would be interesting to reduce field size while maintaining the
current pattern of failure. Future approaches may include individ-
J.P.M. Jaspers, A. Méndez Romero, R. Wiggenraad et al. Radiotherapy and Oncology 156 (2021) 43–48ualized treatment margins based on molecular criteria that define
high – and low risk groups [33]. Additionally, incorporating a data
driven approach based on recurrence probabilities [34], or an
imaging-derived approach based on models of tumor spread [35]
may lead to smaller fields with an identical pattern of recurrence.
Such an approach would, however, require confirmation in
prospective studies with long follow-up.
This study has some limitations, mostly stemming from its ret-
rospective design. It is important to note that the observation of a
lower percentage of recurrence volume covered by a retrospec-
tively constructed 5 mm CTV margin should not be interpreted
as evidence that smaller margins will lead to increased edge
relapse. It can be concluded, however, that not all recurrence vol-
umes are within 5 mm of the GTV. Since no prospective data on
treatment margins below 10–15 mm exist in IDHmG, we feel
GTV-CTV expansions below 10 mm are to be used cautiously.
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